Increasing oncology and rare disease research outsourcing expanding demand for in vivo preclinical services

The increasing complexity of oncology and rare disease research is encouraging pharmaceutical and biotechnology companies to outsource specialized preclinical activities, which will drive the in vivo CRO market growth. Developing therapies for these conditions often requires sophisticated animal models to evaluate efficacy, toxicity, pharmacokinetics, and disease-specific responses before clinical testing. External research organizations provide access to established facilities, specialized scientific expertise, and validated study protocols without requiring sponsors to build and maintain extensive internal infrastructure. Outsourcing also allows drug developers to scale research programs according to pipeline requirements while shortening study preparation timelines, particularly when multiple candidates or disease models need to be assessed. Greater emphasis on translational research is further increasing demand for specialized in vivo studies that can generate evidence relevant to subsequent development stages.

Growing cell and gene therapy pipelines accelerating investments in specialized in vivo testing capabilities

Rapid expansion of cell and gene therapy development is creating demand for highly specialized preclinical evaluation, supporting the in vivo CRO market as developers seek appropriate models for increasingly complex therapeutic platforms. These therapies require detailed assessment of biodistribution, persistence, efficacy, immunogenicity, and potential safety risks that may not be adequately addressed through conventional testing approaches. CROs with capabilities in specialized animal models, tissue analysis, biomarker assessment, and advanced study design can support sponsors in addressing these requirements without extensive investments in internal infrastructure. The need to evaluate delivery systems and therapeutic behavior across different biological conditions is also encouraging the development of more sophisticated in vivo testing capabilities, particularly for therapies targeting difficult-to-treat diseases and genetically mediated disorders.

Rising regulatory complexity in biologics development increasing pharmaceutical reliance on CRO partnerships

More demanding regulatory expectations surrounding biologics development are increasing the need for specialized study design and documentation, thereby supporting growth in the in vivo CRO market. Biologic therapies can present complex safety and pharmacological considerations, requiring carefully designed preclinical studies that generate robust evidence for regulatory submissions. Pharmaceutical companies are increasingly relying on CRO partners with established expertise in regulatory-aligned protocols, animal study management, data interpretation, and quality-controlled research environments. External providers can also help sponsors navigate specialized testing requirements while reducing the operational burden associated with maintaining compliant facilities and trained personnel internally. As development programs become more technically demanding, access to experienced CRO teams enables pharmaceutical developers to coordinate preclinical investigations across different stages of biologics evaluation.